Recent developments include the company's ongoing financial reporting, milestone achievements under licensing agreements, and a planned stockholder vote on a reverse stock split to meet Nasdaq listing requirements.

• Tivic Health Systems reported a net loss of $7.103 million and basic EPS of -$2.17 for the quarter ended June 30, 2026, with cash and cash equivalents of $2.108 million as of that date [S2].
• The company has achieved its first milestone related to validation of inventory for distribution and sales, triggering a $750,000 milestone payment obligation under its amended and restated license agreement with Statera Biopharma [S6][S15][S16][S17].
• A reverse stock split proposal is scheduled for a stockholder vote on August 14, 2026, to increase the stock price to meet Nasdaq's minimum bid price requirement of $1.00, with a ratio between 1-for-5 and 1-for-50 [S2][S7][S9][S13].
• Management oversees cybersecurity risks with periodic reporting to the audit and risk committee and board of directors [S1].

The company holds exclusive rights to a novel TLR5 agonist program with potential applications in Acute Radiation Syndrome and other immunological indications. Successful achievement of development milestones and regulatory approvals could enable Tivic Health to commercialize innovative therapies addressing unmet medical needs. The flexibility in milestone payments, including payment in stock, may help manage cash flow. The company's emerging growth status and Nasdaq listing provide access to capital markets for funding development activities.

Tivic Health is currently operating at a net loss with limited revenue, reflecting the early stage of its product development. The company faces risks related to its ability to meet Nasdaq's minimum bid price requirement, necessitating a reverse stock split that may adversely affect stock liquidity and shareholder value. Milestone and royalty payment obligations create financial commitments that may strain resources. Additional unknown risks, including clinical, regulatory, and market risks, could materially impact the company's business and financial condition.

Tivic Health's moat is based on its exclusive licensing agreements for proprietary TLR5 agonist programs, including Entolimod, which provide it with unique rights to develop and commercialize therapies for Acute Radiation Syndrome and other indications. The company's control over these licensed technologies and its milestone-driven development pathway create barriers to entry for competitors. However, as a development-stage biotech company, its moat depends heavily on successful clinical and regulatory progress and the ability to secure further financing.

• Reverse Stock Split Risks: The proposed reverse stock split may reduce liquidity, increase odd lot shareholders, and potentially cause a decline in stock price, which could adversely affect shareholder value and the company's Nasdaq listing status.
• Financial Losses and Limited Revenue: The company reported significant net losses and minimal revenue, indicating ongoing cash burn and dependence on external financing and milestone payments to fund operations.
• Milestone and Royalty Payment Obligations: Tivic Health has contractual obligations to make milestone payments and royalties under its license agreements, which may impact cash flow and financial flexibility.
• Emerging Growth Company Risks: As an emerging growth company, Tivic Health faces risks related to its early-stage development, including clinical, regulatory, and market uncertainties that could affect its business prospects.
• Cybersecurity Risks: The company acknowledges cybersecurity threats and has management and board oversight processes, but potential cybersecurity incidents could disrupt operations or compromise sensitive information.

• Tivic Health Systems, Inc. is a U.S.-based company with common stock listed on The Nasdaq Capital Market under the symbol TIVC.
• The company is engaged in development and commercialization of licensed products related to Toll-like Receptor 5 (TLR5) agonist programs, including Entolimod for Acute Radiation Syndrome (ARS) and has options for additional indications such as Neutropenia and others.
• Tivic Health acquired exclusive rights to the Phase III TLR5 agonist Entolimod from Statera Biopharma, with an amended and restated exclusive license agreement effective June 18, 2025.
• The license agreement includes milestone payments and royalty obligations, with payments possibly made in cash or company stock at the company's discretion.
• As of June 30, 2026, the company had cash and cash equivalents of $2.108 million and current assets of $3.382 million against current liabilities of $3.046 million, resulting in a current ratio of 1.11 and a cash ratio of 0.69.
• The company reported a net loss of $7.103 million for the quarter ended June 30, 2026, and basic earnings per share of -$2.17 for the same period.
• Revenue reported was $86,000 for the quarter ended June 30, 2025, indicating limited current sales activity.
• The company is an emerging growth company and has engaged in multiple securities purchase agreements, including issuance of Series B Non-Voting Convertible Preferred Stock and warrants.
• A reverse stock split proposal is planned to be voted on August 14, 2026, to increase the stock price to meet Nasdaq's minimum bid price requirement of $1.00, with ratios between 1-for-5 and 1-for-50.
• The reverse stock split may affect liquidity and could increase the number of odd lot shareholders, potentially increasing selling costs and reducing liquidity.
• Management oversees cybersecurity risks with periodic reporting to the audit and risk committee and board of directors.
• The company has achieved its first milestone related to validation of inventory for distribution and sales, triggering a milestone payment obligation of $750,000.
• The company issued Series A Preferred Stock as partial consideration for milestone payments under the license agreement.
• The company has disclosed risks including the potential adverse effects of the reverse stock split on stock price and liquidity, and the possibility of additional unknown risks affecting business and financial condition.